Announcements Trials
Browse Landscape

Phase

Phase 1 15Phase 2 11Phase 3 3Phase 1/2 3

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Colorectal Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 135Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Bevacizumab 95Cyclophosphamide 93Dexamethasone 78Injections 75Docetaxel 72Pemetrexed 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 60130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 56Ipilimumab 54fludarabine 47Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × zimberelimab × Clear all
NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Recruiting
107 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡